Monday, January 12, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Maintains Positive Outlook on Endava with Adjusted Price Target

Elaine Mendonca by Elaine Mendonca
March 1, 2024
in Breaking News
0
Biotechnology Stock Bull Market
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

TD Cowen analyst Bryan Bergin has reiterated his positive outlook on Endava (NYSE: DAVA), maintaining an Outperform rating. However, he has adjusted the price target to $52, down from $85. Despite this revision, the average one-year price target for Endava plc – ADR stands at $72.80, with projections ranging from $53.53 to $98.48.

Analysts surveyed by Capital IQ also give Endava an average outperform rating, with a price target range of $53 to $98.48. The company offers technology services and solutions across various industries including payments, financial services, technology, media, telecom, consumer products, retail, mobility, and healthcare.

Endava leverages its Distributed Enterprise Agile scaling framework to help clients develop digital solutions and maximize their business opportunities.

DAVA Stock Plummets 41.76% on March 1, 2024: Pre-Market Gains Offer Hope for Recovery

On March 1, 2024, DAVA stock experienced a significant drop in price, with shares decreasing by $26.65 since the market last closed. This represents a 41.76% drop in value, with the stock closing at $37.17. However, there seems to be some positive movement in pre-market trading, as the stock has risen by $0.72.

Investors and analysts will be closely monitoring DAVA’s performance in the coming days to see if the pre-market gains will hold and if the stock can start to recover from its recent losses. It will be important to watch for any news or developments that could impact the stock’s price movement.

DAVA Stock Analysis: Mixed Performances on March 1, 2024

On March 1, 2024, DAVA stock experienced mixed performances based on the financial data provided by CNN Money. The total revenue for the company stood at $955.89 million for the past year, showing a 9.84% increase compared to the previous year. However, the total revenue for the second quarter was $227.72 million, reflecting a 4.5% decrease compared to the previous quarter.

Similarly, the net income for DAVA was reported at $113.26 million for the past year, holding flat compared to the previous year. However, the net income for the second quarter was $10.36 million, indicating a significant 33.83% decrease compared to the previous quarter.

Furthermore, the earnings per share (EPS) for DAVA stock was $1.95 for the past year, remaining flat compared to the previous year. However, the EPS for the second quarter was $0.18, showing a substantial 34.3% decrease compared to the previous quarter.

Overall, the financial performance of DAVA stock on March 1, 2024, was a mix of positive and negative indicators. Investors and analysts will closely monitor these financial indicators to assess the overall health and performance of DAVA stock in the coming months. It is essential for investors to conduct thorough research and analysis before making any investment decisions based on the financial data provided.

Tags: DAVA
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Ai Sleeping

Sleep Quality's Impact on Physical and Financial Well-Being

DVY stock news

Truist Securities Analyst Reiterates Hold Recommendation on Best Buy Co

Finances (2)

Truist Securities Analyst Maintains Hold Rating on Integra Lifesciences with Revised Price Target

Recommended

Upcoming FDA Advisory Committee Meeting for Imetelstat A Groundbreaking Treatment for Malignant Stem Cells

2 years ago
Portillo's Stock

Leadership Turmoil Sends Portillo’s Shares to New Low

2 months ago
Dine Brands Global Stock

Dine Brands Stock Faces Potential Downturn

1 month ago
Intel Stock

US Government Considers Taking Equity Stake in Intel

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Alibaba’s Strategic Crossroads: Balancing AI Ambition Against Rising Costs

Vulcan Energy Shares Navigate Investor Reshuffle Amid Major Project Funding

Viking Therapeutics: A Tale of Clinical Progress and Insider Selling

Astera Labs Shares Face Selling Pressure Amid Strong Fundamentals

Institutional Investors Increase Stakes in Realty Income Amid Strategic Refinancing

Procter & Gamble Shares Approach a Critical Juncture

Trending

XRP Stock
Analysis

XRP Market Dynamics: Institutional Pause Meets Accumulation Surge

by Andreas Sommer
January 11, 2026
0

The XRP market is currently defined by a stark divergence in investor behavior. After a powerful rally...

Rocket Lab USA Stock

Rocket Lab’s Stock Momentum Continues Unabated in 2026

January 11, 2026
Eli Lilly Stock

Eli Lilly Charts Aggressive Growth Path with Strategic Acquisitions and Pipeline Advances

January 11, 2026
Alibaba Stock

Alibaba’s Strategic Crossroads: Balancing AI Ambition Against Rising Costs

January 11, 2026
Vulcan Energy Stock

Vulcan Energy Shares Navigate Investor Reshuffle Amid Major Project Funding

January 11, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • XRP Market Dynamics: Institutional Pause Meets Accumulation Surge
  • Rocket Lab’s Stock Momentum Continues Unabated in 2026
  • Eli Lilly Charts Aggressive Growth Path with Strategic Acquisitions and Pipeline Advances

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com